Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $52.46

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $52.6923.

Several research firms have recently commented on IDYA. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Citizens Jmp restated a “market outperform” rating and set a $42.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 1st. Guggenheim lifted their target price on shares of IDEAYA Biosciences from $54.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen cut shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Wedbush raised their price target on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th.

Insider Activity at IDEAYA Biosciences

In other news, CAO Andres Ruiz Briseno sold 9,550 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IDYA. Quantbot Technologies LP acquired a new stake in shares of IDEAYA Biosciences during the second quarter valued at about $43,000. ANTIPODES PARTNERS Ltd grew its stake in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $61,000. Nykredit A S purchased a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at $76,000. Finally, Comerica Bank raised its holdings in shares of IDEAYA Biosciences by 36.5% in the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after buying an additional 672 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $37.59 on Wednesday. The firm has a 50-day moving average of $37.73 and a two-hundred day moving average of $33.71. IDEAYA Biosciences has a 12 month low of $24.24 and a 12 month high of $42.68. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -19.38 and a beta of -0.07.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The company had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The business’s quarterly revenue was up 8800.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.88) EPS. As a group, equities analysts forecast that IDEAYA Biosciences will post -4.38 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses insights from tumor genetics and synthetic lethality—the targeting of vulnerabilities created by specific genetic alterations—to identify therapies intended for molecularly defined patient populations.

IDEAYA’s investigational pipeline includes darovasertib (IDE196), a protein kinase C inhibitor being studied in genetically defined cancers, including metastatic uveal melanoma associated with GNAQ or GNA11 mutations.